The market is now about right about the recovery. Strong new medicines offset weaker devices, but do not justify a higher earnings forecast. I move to Hold after the price decline and retain my $235.60 twelve-month target.
Key points
- $235.60 a share remains my October 2027 target; the lower price moves my rating to Hold.
- $13.11 a share of 2027 core earnings would support today's price at my multiple.
- 2.5% growth in third-quarter devices keeps me cautious about the recovery.
The call
The market is now about right, though still optimistic on profits. Today's price requires 2027 sales growth of 12% at my unchanged profit margin, or a richer multiple. The year-long rally deserves respect, but recent market underperformance and weaker devices argue against paying more.
New medicines outrun device growthQ3 2026 year-over-year growth excluding currency; J&J October 13, 2026 release and call.
I expect steady growth, not a profit breakout. Cancer medicines and Tremfya support my unchanged 2027 forecast, while device competition limits margins. Core excludes amortization, special items and transaction dilution; conditional deal charges would reduce 2027 adjusted earnings to $11.04 a share. December's business review should clarify the gap.
Valuation
| Driver | My estimate |
|---|
| 2027 consolidated sales | $107.2 billion |
| 2027 core earnings per share | $12.40 |
| Base earnings multiple | 17 times |
| Healthcare franchise premium | 2 times |
| October 2027 total multiple | 19 times |
| October 2027 target | $235.60 a share |
My earnings assume a 28.2% core net profit margin and 2.44 billion diluted shares in 2027. The franchise premium rewards dependable demand and replacement medicines, but sustained cash deterioration would erase it; conditional transaction dilution makes the target equivalent to 21.3 times adjusted earnings. Modest downside supports Hold rather than Sell; the target assumes today's business perimeter and requires an ex-distribution reset if Orthopaedics spins off.
Earnings needed to regain today's share priceAnalyst scenarios for 2027 core EPS at 19 times; calculated October 13, 2026.
Risks
- Faster launch adoption could lift earnings; watch medicine growth alongside cash generation, not patient starts alone.
- Device pressure could spread; Boston Scientific expects a competing coronary calcium-treatment device in early 2027, so watch Shockwave's growth.
- Legal payments, a stronger dollar or separation costs could consume cash; watch settlement participation, currency assumptions and final spin terms.
What would change my mind
A credible 2027 outlook above $13.11 a share in core earnings, supported by cash generation, would overturn my cautious forecast.